Can BioAtla’s Oz-V set a new standard in ROR2-targeted therapy for head and neck cancer?
BioAtla and GATC Health advance Ozuriftamab Vedotin into a Phase 3 trial for OPSCC via SPV financing. Discover how this targets cancer and aging together.
Intelligent Bio Solutions taps Syrma Johari to cut drug reader costs and prep for U.S. launch
INBS teams up with Syrma Johari to cut device costs, expand global output, and prep for a 2026 U.S. launch. Find out what this changes for fingerprint drug testing.
Outlook’s bevacizumab for wet AMD rejected again: What’s holding back FDA approval?
FDA rejects Outlook Therapeutics’ ONS-5010 for wet AMD again. Find out what this means for U.S. approval and how European expansion could reshape strategy.
GoldenTree backs Alvotech with $100m financing to accelerate pipeline execution
Alvotech secures $100M loan to fund 2026 biosimilar launches and R&D. Find out how this financing reshapes its global strategy.
How XORTX is linking gout to genetics and reshaping the future of precision uric acid therapies
XORTX is using new genetic research to strengthen its case for oxypurinol in gout and kidney disease. Find out how this could shape the future of precision nephrology.
Ustekinumab biosimilar approved in Japan: Can Samsung Bioepis expand its global autoimmune footprint?
Samsung Bioepis secures Japan approval for its ustekinumab biosimilar with Nipro, marking a key step in Asia’s biosimilar adoption. Find out what this means.
Why Kashiv BioSciences’ Gujarat plant expansion could redefine biomanufacturing in India
Kashiv BioSciences raises INR 648 crore to expand its Gujarat biologics facility. Find out what this means for India’s role in global drug manufacturing.
Coya Therapeutics expands ALS trial into Canada as COYA 302 gains Health Canada clearance
Coya Therapeutics expands its ALS trial for COYA 302 to Canada after Health Canada clearance. Explore what this means for the biotech’s immunotherapy platform.
Enveda’s ENV-6946 enters Phase 1: Can a “multi-biologic in a pill” reshape the future of IBD therapy?
Can Enveda’s ENV-6946 deliver the efficacy of biologics in a pill for IBD? Find out why its triple-cytokine Phase 1 trial is drawing industry attention.
Edwards Lifesciences’ SAPIEN M3 FDA approval marks a turning point for transseptal mitral valve therapy
Edwards Lifesciences’ SAPIEN M3 becomes the first FDA-approved transseptal mitral valve replacement system. Explore how it reshapes TMVR in 2026.